Chronic Obstructive Pulmonary Disease (COPD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Chronic Obstructive Pulmonary Disease (COPD) Marketed and Pipeline Drugs Market Report Overview
COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused both by small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Most people with COPD have both emphysema and chronic bronchitis, but the severity of each type can be different from person to person.
The COPD marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in COPD therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing, and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for COPD.
COPD Marketed Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for COPD marketed drugs are receptor agonist, enzyme inhibitor, receptor antagonist, protein and peptide inhibitor, genes, nucleic acids & related components inhibitor, cells and cell organelle inhibitor, and ion channel blocker among others. Receptor agonist was the most common mechanism of action for COPD marketed drugs.
COPD Marketed Drugs Analysis, by Mechanism of Action
For more MoA insights into the COPD marketed drugs, download a free report sample
COPD Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for COPD marketed drugs are oral, injection, inhalational, topical, and suppository. Most conventional marketed drugs available for COPD are oral drugs.
COPD Marketed Drugs Analysis, by Routes of Administration
For more RoA insights into the COPD marketed drugs, download a free report sample
COPD Marketed Drugs Segmentation by Molecule Type
The key molecule types in the market are small molecule and biologics. The marketed drugs space for COPD is made up of almost equal numbers of small molecules and biologics.
COPD Marketed Drugs Analysis, by Molecule Type
For more molecule type insights into the COPD marketed drugs, download a free report sample
COPD Pipeline Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for COPD pipeline drugs are enzyme inhibitor, receptor antagonist, receptor agonist, biological factor inhibitor, protein and peptide inhibitor, protein and peptide activator, and protein and peptide replacement among others. The COPD pipeline is dominated by enzyme inhibitors, followed by receptor antagonists.
COPD Pipeline Drugs Analysis, by Mechanisms of Action
For more MoA insights into the COPD pipeline drugs market, download a free report sample
COPD Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for COPD pipeline drugs are inhalational, oral, injection, and topical. Most pipeline drugs for COPD are inhalation therapies.
COPD Pipeline Drugs Analysis, by Routes of Administration
For more RoA insights for COPD pipeline drugs market, download a free report sample
COPD Pipeline Drugs Segmentation by Molecule Type
The COPD pipeline drugs comprise mostly small molecule and biologics. More than 80% of the COPD pipeline is dominated by small molecules.
COPD Pipeline Drugs Analysis, by Molecule Types
For more molecule type insights into the COPD pipeline drugs, download a free report sample
COPD Marketed and Pipeline Drugs Market - Top Clinical Trial Sponsors
Some of the top clinical trial sponsors in the COPD marketed and pipeline drugs market are GSK plc, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Novartis AG, Chiesi Farmaceutici SpA, Pearl Therapeutics Inc, Viatris Inc, and Verona Pharma Inc among others.
COPD Marketed Drugs Market Overview
Key Mechanisms of Action | Receptor Agonist, Enzyme Inhibitor, Receptor Antagonist, Protein and Peptide Inhibitor, Genes, Nucleic Acids & Related Components Inhibitor, Cells and Cell Organelle Inhibitor, and Ion Channel Blocker |
Key Routes of Administration | Oral, Injection, Inhalational, Topical, and Suppository |
Key Molecule Types | Small Molecule and Biologics |
COPD Pipeline Drugs Market Overview
Key Mechanisms of Action | Enzyme Inhibitor, Receptor Antagonist, Receptor Agonist, Biological Factor Inhibitor, Protein and Peptide Inhibitor, Protein and Peptide Activator, And Protein and Peptide Replacement |
Key Routes of Administration | Inhalational, Oral, Injection, and Topical |
Key Molecule Types | Small Molecule and Biologics |
Top Clinical Trial Sponsors
|
GSK plc, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Novartis AG, Chiesi Farmaceutici SpA, Pearl Therapeutics Inc, Viatris Inc, and Verona Pharma Inc |
Scope
GlobalData’s COPD Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combine data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the COPD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global COPD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for COPD marketed drugs?
Some of the key mechanisms of action for COPD marketed drugs are receptor agonist, enzyme inhibitor, receptor antagonist, protein and peptide inhibitor, genes, nucleic acids & related components inhibitor, cells and cell organelle inhibitor, and ion channel blocker
-
What are the key routes of administration for COPD marketed drugs?
The key routes of administration for COPD marketed drugs are oral, injection, inhalational, topical, and suppository.
-
What are the key molecule types for COPD marketed drugs?
The key molecule types for COPD marketed drugs are small molecule and biologics.
-
What are the key mechanisms of action for COPD pipeline drugs?
Some of the key mechanisms of action for COPD pipeline drugs are enzyme inhibitor, receptor antagonist, receptor agonist, biological factor inhibitor, protein and peptide inhibitor, protein and peptide activator, and protein and peptide replacement.
-
What are the key routes of administration for COPD pipeline drugs?
The key routes of administration for COPD pipeline drugs are inhalational, oral, injection, and topical.
-
What are the key molecule types for COPD pipeline drugs?
The key molecule types in COPD pipeline drugs are small molecule and biologics
-
Who are the top clinical trial sponsors for the COPD marketed and pipeline drugs market?
Some of the top clinical trial sponsors for the COPD marketed and pipeline drugs market are GSK plc, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Novartis AG, Chiesi Farmaceutici SpA, Pearl Therapeutics Inc, Viatris Inc, and Verona Pharma Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.